Catalent to Acquire Aptuit's Clinical-Trial Supply Business - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Catalent to Acquire Aptuit's Clinical-Trial Supply Business

ePT--the Electronic Newsletter of Pharmaceutical Technology

To further enhance its position in the supply of clinical-trial materials, Catalent Pharma Solutions has agreed to acquire the clinical-trial-supplies business of Aptuit for $410 million on a cash and debt-fee basis.

“This transaction builds important expertise, scale, and capability for our Development & Clinical Services business to better meet our customers’ needs globally,” said John Chiminski, president and CEO of Catalent, in an Aug. 22, 2011, press release. “This transaction also strengthens Catalent’s global leadership in development solutions and advanced delivery technologies for drugs and biologics.”

Catalent’s Development & Clinical Services business offers clinical-supply services, analytical chemistry, respiratory-product development, regulatory consulting, and biologics cell-line development. Catalent says the acquisition positions the company as the number two provider globally in clinical-supply solutions. Catalent offers development services, advanced delivery technologies, and supply solutions for drugs and biologics. The company employs more than 8000 people at 24 facilities worldwide and generated more than $1.7 billion in annual revenue during fiscal year 2010, according to company information.

After exiting the clinical-trial materials supply sector, Aptuit will focus on discovery through mid-phase development. “This agreement puts Aptuit in a better position to focus on the scientific excellence that our customers want,” said Timothy C. Tyson, chair and CEO of Aptuit, in the press release. “Focusing on our expertise in discovery and development services leverages our leadership position and allows us to concentrate on delivering high-growth, high-value scientific services from discovery to mid-phase development.”

The deal is subject to customary closing conditions, including approval from regulatory authorities. The transaction is expected to be complete by the end of the calendar year.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here